Trade ImmuCell - ICCC CFD

ImmuCell Company profile

About ImmuCell Corporation

ImmuCell Corporation is an animal health company. The Company is engaged in development, acquisition, manufacture and sale of products that improve the health and productivity of dairy and beef cattle. It manufactures and markets the First Defense product line for the prevention of scours in newborn dairy and beef calves. It expanded this line into five different products with formulations targeting E. coli and coronavirus pathogens as well as E. coli, coronavirus and rotavirus pathogens. Its Tri-Shield First Defense product line extension is calf-level, passive antibody product providing immediate immunity against E. coli, coronavirus and rotavirus. These product line provides Immediate Immunity to newborn calves. The Company is engaged in development of Re-Tain, a Nisin treatment for subclinical mastitis in lactating dairy cows. Its products reduce the use of traditional antibiotics in food producing animals.

Financial summary

BRIEF: For the nine months ended 30 September 2021, ImmuCell Corporation revenues increased 19% to $13.8M. Net loss decreased 87% to $152K. Revenues reflect First Defense® product line segment increase of 44% to $9.5M, Other animal health segment increase of 83% to $186K, United States segment increase of 18% to $12.2M, Others segment increase of 28% to $1.6M.

Equity composition

Common Stock $.10 Par, 12/10, 8M auth., 3,261,148 issd., less 287,496 shs. in Treas. @ $635K. Insiders own 26.70%. PO 5/87, 966,000 Units (100 Common + 5 Warrants) @ $7/Unit by Stuart James. 7/90, 1-for-100 reverse stock split.